Copyright
©The Author(s) 2023.
World J Gastroenterol. Nov 21, 2023; 29(43): 5818-5833
Published online Nov 21, 2023. doi: 10.3748/wjg.v29.i43.5818
Published online Nov 21, 2023. doi: 10.3748/wjg.v29.i43.5818
Table 6 Univariate and multivariate analysis of knowledge
Variables | Univariate analysis | Multivariate analysis | ||
OR (95%CI) | P value | OR (95%CI) | P value | |
Gender | ||||
Male | 1.09 (0.62-1.92) | 0.751 | ||
Female | Ref | |||
Age | ||||
≤ 20 | Ref | Ref | ||
20-30 | 2.80 (1.10-7.09) | 0.030 | 3.01 (0.97-9.38) | 0.057 |
30-40 | 2.17 (0.84-5.63) | 0.111 | 4.06 (1.04-15.82) | 0.043 |
> 40 | 0.76 (0.33-1.75) | |||
Ethnicity | ||||
Han | 3.83 (1.13-12.94) | 0.031 | 3.70 (0.80-16.97) | 0.093 |
Minorities | Ref | Ref | ||
Residence | ||||
Rural | Ref | Ref | ||
City | 3.08 (1.56-6.07) | 0.001 | 1.69 (0.74-3.84) | 0.213 |
Suburb/urban-rural combination | 1.95 (0.97-3.90) | 0.060 | 1.33 (0.58-3.03) | 0.496 |
Education | ||||
Primary school and below | Ref | |||
Middle school | 2.99 (1.15-7.76) | 0.025 | 3.98 (1.29-12.33) | 0.017 |
High school/technical secondary school | 11.80 (4.20-33.17) | < 0.001 | 14.06 (3.92-50.38) | < 0.001 |
Junior college/bachelor’s degree and above | 20.70 (7.75-55.28) | < 0.001 | 15.20 (4.15-55.65) | < 0.001 |
Work status | ||||
Employed | 4.07 (2.23-7.41) | < 0.001 | 1.34 (0.63-2.85) | 0.444 |
Other | Ref | Ref | ||
Monthly per capita income | ||||
< 5000 | Ref | Ref | ||
5000-10000 | 3.94 (1.84-8.43) | < 0.001 | 2.04 (0.81-5.18) | 0.133 |
> 10000 | 2.46 (1.17-5.18) | 0.018 | 0.90 (0.34-2.36) | 0.823 |
Marital status | ||||
Unmarried or other | Ref | Ref | ||
Married | 0.61 (0.35-1.07) | 0.083 | 0.85 (0.33-2.16) | 0.734 |
Smoking habit | ||||
No (no smoking) | Ref | |||
Yes (smoking or used to smoke) | 0.60 (0.33-1.12) | 0.10 | ||
Drinking habit | ||||
No (no drinking) | Ref | |||
Yes (drinking or used to drink) | 0.85 (0.49-1.50) | 0.584 | ||
What kind of IBD is being diagnosed | ||||
Ulcerative colitis | 0.50 (0.29-0.85) | 0.011 | 0.57 (0.28-1.18) | 0.132 |
Crohn’s disease | Ref | Ref | ||
Duration of IBD | ||||
< 1 yr | 1.14 (0.54-2.39) | 0.729 | ||
1-2 yr | 0.98 (0.39-2.45) | 0.964 | ||
> 2 yr | Ref | |||
Ostomy? | ||||
Yes | 0.51 (0.21-1.23) | 0.135 | ||
No | Ref | |||
Comorbidities | ||||
Yes | 0.62 (0.32-1.19) | 0.149 | ||
None | Ref | |||
Family history of IBD | ||||
Yes | 1.86 (0.23-15.16) | 0.560 | ||
No | Ref | |||
Surgical history | ||||
Yes | 1.15 (0.67-1.97) | 0.613 | ||
No | Ref | |||
History of drug allergy | ||||
Yes | 1.40 (0.60-3.29) | 0.433 | ||
No | Ref | |||
What kind of treatment is being received? | ||||
5-aminosalicylic acid drugs (e.g., mesalazine) | Ref | |||
Glucocorticoids | - | - | ||
Immunosuppressants (e.g., azathioprine, tacrolimus, cyclosporine, etc.) | 0.46 (0.07-2.99) | 0.418 | ||
Biological agents (e.g., infliximab, vedolizumab, ustekinumab) | 2.11 (0.77-5.80) | 0.148 | ||
Biological agents + immunosuppressants | 1.69 (0.34-8.40) | 0.520 | ||
Biological agents + 5-aminosalicylic acid drugs | - | - |
- Citation: Shao XX, Fang LY, Guo XR, Wang WZ, Shi RX, Lin DP. Knowledge, attitude, and practice of patients living with inflammatory bowel disease: A cross-sectional study. World J Gastroenterol 2023; 29(43): 5818-5833
- URL: https://www.wjgnet.com/1007-9327/full/v29/i43/5818.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i43.5818